R-2-Hydroxyglutarate Induces RIPK1-Dependent Necroptosis Via Inhibition of KDM2B in Myeloid Malignancies
Shuanghong Zhu,Chen Mei,Lingxu Jiang,Wenli Yang,Yingwan Luo,Lu Wang,Hua Zhang,Peipei Lin,Weilai Xu,Xinping Zhou,Chuying Shen,Wei Lang,Yanling Ren,Haiyang Yang,Chenxi Lu,Liya Ma,Yi Le,Xin Huang,Jie Jin,Hongyan Tong
DOI: https://doi.org/10.2139/ssrn.3696871
2020-01-01
Abstract:Background: The role of R-2-hydroxyglutarate (R-2HG), which is derived from mutant isocitrate dehydrogenase 1/2 (IDH1/2) enzymes, is controversial in myeloid malignancies. Although confirmed to promote leukemogenesis, R-2HG has recently been reported to exert anti-tumor activity in leukemia and glioma.Methods: Microarray and GSEA (gene set enrichment analysis) were used to identify core regulators in R-2HG-induced tumor cell death. To confirm the occurrence of necroptosis, we employed fluorescent apoptosis/necrosis (FAN) assay, Co-immunoprecipitation (Co-IP) and transmission electron microscopy.Findings: Here, we found that R-2HG increased the expression of receptor-interacting protein kinase 1 (RIPK1) and induced RIPK1-dependent necroptosis, thereby inhibiting the proliferation of malignant myeloid cells. Moreover, during the early stages of R-2HG treatment, higher levels of necroptosis was observed in comparison with apoptosis. The occurrence of R-2HG-induced necroptosis was independent of apoptosis and the G0/G1 cell cycle arrest. Additionally, the increased RIPK1 expression could be induced by the hypoexpression of lysine demethylase 2B (KDM2B), an α-KG-dependent dioxygenase. Furthermore, the downregulation of KDM2B could inhibit the proliferation of malignant myeloid cells via triggering necroptosis. We also found that low RIPK1 expression was significantly associated with a shorter overall survival, larger percentage of bone marrow blasts, and higher risk of leukemic transformation in 122 patients with myelodysplastic syndrome.Interpretation: Our study showed that R-2HG induces RIPK1-dependent necroptosis via the inhibition of KDM2B in malignant myeloid cells. Thus, KDM2B may represent a potential therapeutic target for myeloid malignancies.Funding Statement: This work was supported by grants from National Natural Science Foundation of China Grants (81970117, 81470290, and 81800121). Declaration of Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paperEthics Approval Statement: Sample collection and analysis were approved by the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine, and written informed consent was obtained from all patients. All studies were approved by the Ethics Committee for Laboratory Animals of the First Affiliated Hospital, Zhejiang University School of Medicine.